List of Wound Healing Companies in United Kingdom - 5

AVITA Medical (NASDAQ: RCEL, ASX:AVH) is a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a Biosynthetic Wound Matrix, in the United States.

Biotherapy Services Ltd. (BTS) is a pharmaceutical biotechnology company developing and delivering novel autologous therapies for complex and chronic wounds 🥽 🥼. Biotherapy Services, composed of clinicians, technicians, and healthcare managers, was created to bring the most effective platelet-enriching technology to medical practices in the UK and Eire 👩‍🔬 👨‍⚕️. The company has developed proprietary expertise and a unique GMP standard operational service model to provide the RAPID™ Biodynamic Haematogel autologous wound care treatment, targeting complex and chronic wounds such as Diabetic Foot Ulcers and Pressure Sores 🦵️ 🦶️. The RAPID™ Gel harnesses the patient’s own platelets to speed healing, growth, repair, and recovery 🧬️. BTS is currently conducting the RAPID-1 Trial to investigate the efficacy of RAPID™ Gel in wound closure compared to usual and customary care 🔎.

At Convatec, #ForeverCaring is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. #ForeverConvatec

Corryn Biotechnologies is developing a technology to fabricate and deposit biomimetic nano- and micro-fibrous wound dressings directly upon wound sites at the point of care. This technology aims to significantly reduce the drawbacks of current commercial products and their lack of regenerative properties. These dressings have been shown to be formable from several different material platforms both with and without additives known to be beneficial to wound healing. Our technology comprises an in-house developed handheld applicator device, loaded with sealed sterile cartridges of proprietary material formulations which are converted to fibrous substrates through a process known as electrospinning and deposited painlessly onto the patient.

Chronic wounds affect ~100m people around the world, impacting quality of life & placing a huge burden on health systems. Despite the many innovations in wound care over the years, chronic wound healing rates have barely improved. Change is needed – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations in chronic wound care. SolasCure is at the forefront of addressing this demand, aiming to shift the current treatment paradigm with a high impact therapeutic approach to debridement, with the goal of enabling dramatic improvements in healing rates and patients’ quality of life. Aurase Wound Gel aims to address the huge unmet need for easy & effective debridement to return wounds to healing. It combines the enzyme Tarumase with hydrogel to debride wounds, reduce biofilm & promote healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation. After successful Phase IIa trials, SolasCure is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds. For more information, you can find our peer-reviewed publications here: Clinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805 Preclinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14079 The importance of our innovative technology has been widely recognised: - Innovate UK Global Incubator Programme (Innovate UK, the UK’s Innovation Agency), Texas Medical Center, 2024 - Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024 - EIC Accelerator Grant (European Innovation Council), 2023 - Life Sciences Innovator (UK Department for Trade and Business), 2023 - EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022 - Winner 2019 URGO Mentorship Programme. Visit us at www.solascure.com